Arcus Biosciences Inc
RCUS23.100USD
-0.020-0.09%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
2.47BMarket Cap
LossP/E TTM
More Details of Arcus Biosciences Inc Company
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Arcus Biosciences Inc Info
Ticker SymbolRCUS
Company nameArcus Biosciences Inc
IPO dateMar 15, 2018
CEORosen (Terry J)
Number of employees627
Security typeOrdinary Share
Fiscal year-endMar 15
Address3928 Point Eden Way
CityHAYWARD
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code94545-3719
Phone15106946200
Websitehttps://arcusbio.com/
Ticker SymbolRCUS
IPO dateMar 15, 2018
CEORosen (Terry J)
Company Executives of Arcus Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Juan Carlos Jaen, Ph.D.
Dr. Juan Carlos Jaen, Ph.D.
President, Co-Founder
President, Co-Founder
1.44M
-0.15%
Dr. Yasunori Kaneko, M.D.
Dr. Yasunori Kaneko, M.D.
Lead Independent Director
Lead Independent Director
943.86K
+1.43%
Dr. David L. Lacey, M.D.
Dr. David L. Lacey, M.D.
Independent Director
Independent Director
62.55K
+27.00%
Dr. Antoni Ribas, M.D., Ph.D.
Dr. Antoni Ribas, M.D., Ph.D.
Independent Director
Independent Director
43.80K
+43.60%
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
30.20K
+78.70%
Mrs. Nicole Lambert
Mrs. Nicole Lambert
Independent Director
Independent Director
28.90K
+85.26%
Dr. Andrew Perlman, M.D., Ph.D.
Dr. Andrew Perlman, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Richard Markus, M.D., Ph.D.
Mr. Richard Markus, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Kathryn E. Falberg
Ms. Kathryn E. Falberg
Independent Director
Independent Director
--
--
Ms. Jennifer A. Jarrett
Ms. Jennifer A. Jarrett
Chief Operating Officer
Chief Operating Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Juan Carlos Jaen, Ph.D.
Dr. Juan Carlos Jaen, Ph.D.
President, Co-Founder
President, Co-Founder
1.44M
-0.15%
Dr. Yasunori Kaneko, M.D.
Dr. Yasunori Kaneko, M.D.
Lead Independent Director
Lead Independent Director
943.86K
+1.43%
Dr. David L. Lacey, M.D.
Dr. David L. Lacey, M.D.
Independent Director
Independent Director
62.55K
+27.00%
Dr. Antoni Ribas, M.D., Ph.D.
Dr. Antoni Ribas, M.D., Ph.D.
Independent Director
Independent Director
43.80K
+43.60%
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
30.20K
+78.70%
Mrs. Nicole Lambert
Mrs. Nicole Lambert
Independent Director
Independent Director
28.90K
+85.26%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
License and development services revenue
152.00M
95.00%
Collaboration revenue
8.00M
5.00%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
License and development services revenue
152.00M
95.00%
Collaboration revenue
8.00M
5.00%
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Gilead Sciences Inc
25.58%
BlackRock Institutional Trust Company, N.A.
8.19%
The Vanguard Group, Inc.
5.39%
Point72 Asset Management, L.P.
3.53%
Woodline Partners LP
3.07%
Other
54.25%
Shareholders
Shareholders
Proportion
Gilead Sciences Inc
25.58%
BlackRock Institutional Trust Company, N.A.
8.19%
The Vanguard Group, Inc.
5.39%
Point72 Asset Management, L.P.
3.53%
Woodline Partners LP
3.07%
Other
54.25%
Shareholder Types
Shareholders
Proportion
Corporation
25.58%
Investment Advisor
25.42%
Hedge Fund
14.42%
Investment Advisor/Hedge Fund
13.42%
Individual Investor
4.49%
Research Firm
3.09%
Venture Capital
2.37%
Pension Fund
0.59%
Bank and Trust
0.25%
Other
10.37%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
427
71.30M
52.26%
-5.17M
2025Q2
441
104.25M
98.12%
+5.20M
2025Q1
461
106.23M
100.41%
+7.59M
2024Q4
458
92.45M
92.67%
-8.14M
2024Q3
459
92.17M
107.84%
+6.16M
2024Q2
456
90.82M
107.03%
+3.48M
2024Q1
456
91.60M
108.07%
-2.14M
2023Q4
455
76.21M
102.30%
-15.07M
2023Q3
450
76.35M
103.06%
-17.88M
2023Q2
441
78.29M
107.10%
-16.66M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Gilead Sciences Inc
31.42M
29.53%
--
--
Jul 13, 2025
BlackRock Institutional Trust Company, N.A.
10.09M
9.48%
+407.08K
+4.20%
Jun 30, 2025
The Vanguard Group, Inc.
6.54M
6.15%
-131.56K
-1.97%
Jun 30, 2025
Point72 Asset Management, L.P.
5.97M
5.61%
+3.10M
+108.11%
Jun 30, 2025
Woodline Partners LP
4.00M
3.76%
-1.13M
-21.99%
Jun 30, 2025
Suvretta Capital Management, LLC
3.69M
3.47%
+1.13M
+44.05%
Jun 30, 2025
State Street Investment Management (US)
3.63M
3.41%
-65.66K
-1.78%
Jun 30, 2025
Rosen Terry Jay
2.57M
2.42%
-472.90K
-15.53%
Mar 01, 2025
Fidelity Management & Research Company LLC
2.27M
2.13%
-1.86M
-45.07%
Jun 30, 2025
Invus Financial Advisors, LLC
1.61M
1.51%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
2.68%
Virtus LifeSci Biotech Clinical Trials ETF
1.43%
ALPS Medical Breakthroughs ETF
0.9%
Invesco S&P SmallCap Health Care ETF
0.84%
Tema Oncology ETF
0.75%
Invesco S&P SmallCap 600 Pure Growth ETF
0.69%
iShares Health Innovation Active ETF
0.52%
State Street SPDR S&P Biotech ETF
0.34%
Direxion Daily S&P Biotech Bull 3X Shares
0.21%
State Street SPDR S&P 600 Small Cap Growth ETF
0.19%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion2.68%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.43%
ALPS Medical Breakthroughs ETF
Proportion0.9%
Invesco S&P SmallCap Health Care ETF
Proportion0.84%
Tema Oncology ETF
Proportion0.75%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion0.69%
iShares Health Innovation Active ETF
Proportion0.52%
State Street SPDR S&P Biotech ETF
Proportion0.34%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.21%
State Street SPDR S&P 600 Small Cap Growth ETF
Proportion0.19%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Arcus Biosciences Inc?
The top five shareholders of Arcus Biosciences Inc are:
Gilead Sciences Inc holds 31.42M shares, accounting for 29.53% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 10.09M shares, accounting for 9.48% of the total shares.
The Vanguard Group, Inc. holds 6.54M shares, accounting for 6.15% of the total shares.
Point72 Asset Management, L.P. holds 5.97M shares, accounting for 5.61% of the total shares.
Woodline Partners LP holds 4.00M shares, accounting for 3.76% of the total shares.
Gilead Sciences Inc holds 31.42M shares, accounting for 29.53% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 10.09M shares, accounting for 9.48% of the total shares.
The Vanguard Group, Inc. holds 6.54M shares, accounting for 6.15% of the total shares.
Point72 Asset Management, L.P. holds 5.97M shares, accounting for 5.61% of the total shares.
Woodline Partners LP holds 4.00M shares, accounting for 3.76% of the total shares.
What are the top three shareholder types of Arcus Biosciences Inc?
The top three shareholder types of Arcus Biosciences Inc are:
Gilead Sciences Inc
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Gilead Sciences Inc
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
How many institutions hold shares of Arcus Biosciences Inc (RCUS)?
As of 2025Q3, 427 institutions hold shares of Arcus Biosciences Inc, with a combined market value of approximately 71.30M, accounting for 52.26% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -45.86%.
What is the biggest source of revenue for Arcus Biosciences Inc?
In FY2025Q2, the License and development services revenue business generated the highest revenue for Arcus Biosciences Inc, amounting to 152.00M and accounting for 95.00% of total revenue.
